# National Medical Products Administration

Type: Company

Source: GetYourBrief — https://getyourbrief.com/entity/national-medical-products-administration
Canonical HTML page: https://getyourbrief.com/entity/national-medical-products-administration

## Timeline

- **2026-06-22**: NMPA releases 2025 report — China's National Medical Products Administration publishes comprehensive statistics on the record-breaking clinical trial activity.
- **2026-03-24**: Phase III Initiation — First patient dosed at Peking Union Medical College Hospital in China.
- **2026-03-24**: Phase III Initiation — First patient dosed at Peking Union Medical College Hospital in China.
- **2026-02**: Cost advantages quantified — At the Outsourcing in Clinical Trials conference in California, China's trial costs were reported 50–60% lower and timelines faster than in the US.
- **2026-01-15**: Regulatory Designations — FDA grants Fast Track and NMPA grants Breakthrough Therapy status.
- **2026-01**: Regulatory Designations — HMI-115 receives FDA Fast Track and NMPA Breakthrough Therapy designations.
- **2026**: Trial Expansion — Continued enrollment across global multicenter sites for the 24-week study.
- **2025-Q4**: Phase II Data Publication — Results showing efficacy without hormonal side effects published in The Lancet.
- **2025-Q4**: Phase II Completion — Global multicenter Phase II trial results published in The Lancet showing efficacy and safety.
- **2025**: Record trial count achieved — 5,215 clinical drug trials registered, more than double 2020, with 57.5% being new drug trials and cancer treatments dominating.
- **2020**: Pre-surge baseline — Approximately 2,600 clinical drug trials registered in China (implied by 2025 doubling).

## Recent coverage (4 stories, network-wide)

### 5,215 China Trials in 2025 Cost 60% Less Than US: Security Risks Loom
2026-06-24 10:39:39 · Sector: health · Sentiment: Neutral · Impact: 7/10 · Sources: 2

China’s clinical drug trials hit a record 5,215 in 2025, with costs 50–60% lower than in the US. This surge, driven by Beijing’s biotech ambitions, is reshaping global drug development and raising national security concerns in Washington as Chinese firms gain dominance in cancer and vaccine research.
Full story: https://gethealthbrief.com/story/china-record-drug-trials-2025-cost-security

### China’s 5,215 Clinical Trials in 2025 Double Since 2020; Cancer Drugs Lead Surge
2026-06-24 10:39:00 · Sector: bio · Sentiment: Neutral · Impact: 7/10 · Sources: 2

With 5,215 clinical drug trials registered in 2025, China has more than doubled its pipeline since 2020, with 57.5% focused on novel drugs and cancer treatments topping the list. The rapid expansion and 50–60% cost advantage compared to the US are reshaping the global biopharma landscape, but Washington is scrutinizing implications for drug quality and security.
Full story: https://getbiobrief.com/story/china-5215-clinical-trials-2025-oncology-lead

### Hope Medicine Doses First Patient in Phase III Trial for Endometriosis Therapy
2026-03-25 12:13:15 · Sector: bio · Sentiment: Positive · Impact: 7/10 · Sources: 10

Hope Medicine Inc. has initiated dosing in its Phase III clinical trial for HMI-115, a first-in-class non-hormonal monoclonal antibody for endometriosis. This milestone marks the first time a non-hormonal treatment for this condition has reached Phase III development globally, offering a potential alternative to traditional hormonal therapies.
Full story: https://getbiobrief.com/story/hope-medicine-hmi-115-phase-iii-endometriosis

### Hope Medicine Doses First Phase III Patient for Non-Hormonal Endometriosis Drug
2026-03-25 12:12:33 · Sector: health · Sentiment: Positive · Impact: 7/10 · Sources: 10

Hope Medicine Inc. has initiated Phase III dosing for HMI-115, the first non-hormonal monoclonal antibody for endometriosis to reach this clinical stage. This milestone, supported by FDA Fast Track and NMPA Breakthrough designations, signals a potential shift away from traditional hormone-suppressing therapies in women's health.
Full story: https://gethealthbrief.com/story/hope-medicine-hmi115-phase-3-endometriosis

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getyourbrief.com/guides/methodology for the full editorial methodology.